Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR 37.5 mg / 75 mg capsules (venlafaxine ...

Fifteen years ago, Izzy Judd was relaxing on the beach in Australia when she suddenly felt gripped by fear and unable to ...

A new research study showcases compelling evidence for AI-based mental health apps. Limitations exist. An AI Insider scoop.

When an addiction and a mental health disorder coexist—a condition known as dual disorder—scientific evidence indicates that ...

Over 630 GPs in Singapore are now part of a scheme to treat mental health, with more polyclinics offering mental health ...

Interview | Angela Sant'Albano's incredible performance as Grace helps Resident Evil Requiem dethrone Resident Evil 7 as the ...

While coping ahead is a helpful strategy for managing worry, dreading ahead causes a host of problems. Individuals can ...

A retrospective study evaluated adults with both PTSD and depression who received a novel sequential bilateral TMS protocol ...

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today reported that it holds approximately $75 million ...

Objectives To translate and culturally adapt six self-report measures for depression, anxiety, post-traumatic stress disorder ...

A Swedish national cohort study shows some GLP-1s — semaglutide in particular — are associated with reduced risk of psychiatric decline in patients with depression or anxiety.